EGFR and pneumonitis: Oshima et al.67 also evaluated the incidence of pneumonitis in patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) with or without nivolumab, which produced incidence rates of 25.7% and 4.59%, respectively.